During the last session, Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s traded shares were 4.56 million, with the beta value of the company hitting 1.60. The 52-week high for the CTXR share is $1.07, that puts it down -529.41 from that peak though still a striking 5.88% gain since the share price plummeted to a 52-week low of $0.16. The company’s market capitalization is $31.89M, and the average intraday trading volume over the past 10 days was 5.27 million shares, and the average trade volume was 1.55 million shares over the past three months.
Citius Pharmaceuticals Inc (CTXR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CTXR has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Citius Pharmaceuticals Inc (CTXR) registered a -2.83% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.83% in intraday trading to $0.17, hitting a weekly high. The stock’s 5-day price performance is -49.73%, and it has moved by -53.77% in 30 days. Based on these gigs, the overall price performance for the year is -78.61%. The short interest in Citius Pharmaceuticals Inc (NASDAQ:CTXR) is 11.79 million shares and it means that shorts have 13.22 day(s) to cover.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Statistics show that Citius Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Citius Pharmaceuticals Inc (CTXR) shares have gone down -75.87% during the last six months, with a year-to-date growth rate less than the industry average at -8.33% against 16.60.
Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 7.06M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.21%. While earnings are projected to return -4.55% in 2024.
CTXR Dividends
Citius Pharmaceuticals Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Citius Pharmaceuticals Inc insiders own 6.37% of total outstanding shares while institutional holders control 12.26%, with the float percentage being 13.09%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 66.0 institutions own stock in it. As of 2024-06-30, the company held over 10.16 million shares (or 6.3845% of all shares), a total value of $5.93 million in shares.
The next largest institutional holding, with 6.33 million shares, is of VANGUARD GROUP INC’s that is approximately 3.9776% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.69 million.
